Lansoprazole as a rescue agent in chemoresistant tumors: A phase I/II study in companion animals with spontaneously occurring tumors

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Spugnini, Enrico P ^a   Baldi, Alfonso ^b   Buglioni, Sabrina ^c   Carocci, Francesca ^c   Milesi de Bazzichini, Giulia ^d   Betti, Gianluca ^d   Pantaleo, Ilaria ^d   Menicagli, Francesco ^e   Citro, Gennaro ^a   Fais, Stefano ^f  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Ambulatorio Veterinario Le Accademie   (Italy)

^d Ambulatorio Veterinario Farnesina   (Italy)

^e Centro Veterinario Gianicolense   (Italy)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Carboplatin; Chemotherapy; Lansoprazole; Mitoxantrone; Proton pump

Indexed keywords

ANTIBIOTIC AGENT; ASPARAGINASE; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CHLORPHENIRAMINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; LANSOPRAZOLE; METOCLOPRAMIDE; MITOXANTRONE; PIROXICAM; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; PROCARBAZINE; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE; VINCRISTINE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT;

ACHLORHYDRIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANIMAL EXPERIMENT; ANOREXIA; APPETITE; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER PAIN; CANCER REGRESSION; CANCER RESISTANCE; CAT; DIARRHEA; DOG; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FIBROSARCOMA; FLATULENCE; GASTRIC HYPERACIDITY; GROOMING; HOSPITALIZATION; INFECTION; KARNOFSKY PERFORMANCE STATUS; LIPOSARCOMA; LYMPHOMA; LYMPHOSARCOMA; MALE; MELANOMA; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; NASAL LYMPHOSARCOMA; NEUTROPENIA; NEUTROPHILIA; NOCICEPTION; NONHUMAN; NOSE CARCINOMA; OSTEOSARCOMA; PET ANIMAL; QUALITY OF LIFE; SKIN CARCINOMA; SKIN LYMPHOMA; SKIN LYMPHOSARCOMA; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ULCER; VOMITING; WEIGHT BEARING; WEIGHT GAIN; ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; COMPASSIONATE USE; DRUG EFFECT; DRUG RESISTANCE; HUMAN; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; ANTINEOPLASTIC AGENTS; CATS; COMPASSIONATE USE TRIALS; DOGS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84455173776     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-221     Document Type: Article

References (50)

1. Finbow ME, Harrison MA. The vacuolar H+-ATPase: a universal proton pump of eukaryotes. Biochem J 1997, 324:697-712. 1218484, 9210392.
2. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 2007, 8:917-929. 10.1038/nrm2272, 17912264.
3. Cipriano DJ, Wang Y, Bond S, Hinton A, Jefferies KC, Qi J, Forgac M. Structure and regulation of the vacuolar ATPases. Biochim Biophys Acta 2008, 1777:599-604. 10.1016/j.bbabio.2008.03.013, 2467516, 18423392.
4. Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys 2008, 476:33-42. 10.1016/j.abb.2008.03.025, 2543942, 18406336.
5. Sautin YY, Lu M, Gaugler A, Zhang L, Gluck SL. Phosphatidylinositol 3-kinase-mediated effects of glucose on vacuolar H+-ATPase assembly, translocation, and acidification of intracellular compartments in renal epithelial cells. Mol Cell Biol 2005, 25:575-589. 10.1128/MCB.25.2.575-589.2005, 543406, 15632060.
6. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science 2003, 299:1400-1403. 10.1126/science.1080106, 12610307.
7. Feng Y, Forgac M. A novel mechanism for regulation of vacuolar acidification. J Biol Chem 1992, 267:19769-19772.
8. Feng Y, Forgac M. Cysteine 254 of the 73-kDa A subunit is responsible for inhibition of the coated vesicle (H+)-ATPase upon modification by sulfhydryl reagents. J Biol Chem 1992, 267:5817-5822.
9. Feng Y, Forgac M. Inhibition of vacuolar H(+)-ATPase by disulfide bond formation between cysteine 254 and cysteine 532 in subunit A. J Biol Chem 1994, 269:13224-13230.
10. Forgac M. The vacuolar H+-ATPase of clathrin-coated vesicles is reversibly inhibited by Snitrosoglutathione. J Biol Chem 1999, 274:301-1305.
11. Xu T, Forgac M. Subunit D (Vma8p) of the yeast vacuolar H+-ATPase plays a role in coupling of proton transport and ATP hydrolysis. J Biol Chem 2000, 275:22075-22081. 10.1074/jbc.M002983200, 10801866.
12. Kawasaki-Nishi S, Bowers K, Nishi T, Forgac M, Stevens TH. The amino-terminal domain of the vacuolar proton-translocating ATPase a subunit controls targeting and in vivo dissociation, and the carboxyl-terminal domain affects coupling of proton transport and ATP hydrolysis. J Biol Chem 2001, 276:47411-47420. 10.1074/jbc.M108310200, 11592965.
13. Saitoh O, Wang WC, Lotan R, Fukuda M. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 1992, 267:5700-5711.
14. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 2003, 5:533-545. 1502575, 14965446.
15. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899. 10.1038/nrc1478, 15516961.
16. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 2007, 67:10627-10630. 10.1158/0008-5472.CAN-07-1805, 18006801.
17. Nishi T, Forgac M. The vacuolar (H+)-ATPases nature's most versatile proton pumps. Nat Rev Mol Cell Biol 2002, 3:94-103. 10.1038/nrm729, 11836511.
18. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 1993, 265:1015-29.
19. Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, Xie L, Yao G, Shu H, Yao M, Wan D, Gu J, Yang S. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 2005, 65:6843-6849. 10.1158/0008-5472.CAN-04-3822, 16061667.
20. Mahoney BP, Raghunand N, Bagget B, Gillies RJ. Tumor acidity, ione trapping and chemotherapeutics I. Acid pH effects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003, 66:1207-1218. 10.1016/S0006-2952(03)00467-2, 14505800.
21. Simon S, Roy D, Schindler M. Intracellular Ph and the control of multidrug resistance. Proc Nat Acad Sci USA 1993, 91:1128-1132.
22. Raghunand N, Mahoney BP, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. BiochemPharmacol 2003, 66:1219-1229.
23. Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 1999, 57:1037-1046. 10.1016/S0006-2952(99)00022-2, 10796074.
24. Raghunand N, Martínez-Zaguilán R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 1999, 57:1047-1058. 10.1016/S0006-2952(99)00021-0, 10796075.
25. Bobichon H, Colin M, Depierreux C, Liautaud-Roger F, Jardillier JC. Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J Exp Ther Oncol 1996, 1:49-61.
26. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004, 96:1702-1713. 10.1093/jnci/djh305, 15547183.
27. De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Mina PD, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010, 127:207-19. 10.1002/ijc.25009, 19876915.
28. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, Kohno K. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 2001, 93:869-874. 10.1002/ijc.1418, 11519050.
29. Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K. Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem 2002, 277:36534-36543. 10.1074/jbc.M202605200, 12133827.
30. Torigoe T, Izumi H, Yoshida Y, Ishiguchi H, Okamoto T, Itoh H, Kohno K. Low pH enhances Sp1 DNA binding activity and interaction with TBP. Nucleic Acids Res 2003, 31:4523-4530. 10.1093/nar/gkg487, 169877, 12888513.
31. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007, 67:5408-17. 10.1158/0008-5472.CAN-06-4095, 17545622.
32. Thamm DH, Vail DM. Mast cell tumors. Small Animal Clinical Oncology 2007, 402-424. Philadelphia, PA: WB Saunders Co, Withrow SJ, MacEwen EG, 4.
33. Brooks D, Watson GL. Omeprazole in a dog with gastrinoma. J Vet Intern Med 1997, 11:379-381. 10.1111/j.1939-1676.1997.tb00485.x, 9470166.
34. Fukushima R, Ichikawa K, Hirabayashi M, Yamagami T, Koyama H, Hirose H, Uchino T. A case of canine gastrinoma. J Vet Med Sci 2004, 66:993-995. 10.1292/jvms.66.993, 15353855.
35. Hughes SM. Canine gastrinoma: a case study and literature review of therapeutic options. N Z Vet J 2006, 54:242-247. 10.1080/00480169.2006.36705, 17028663.
36. Ward CR. Gastrointestinal endocrine disease. 2010, 1862-1865. Textbook of Veterinary Internal Medicine, Ettinger SJ, Feldman EC, Seventh, Saunders, St. Louis.
37. Klohs WD, Steinkampf RW. The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol 1988, 34:180-185.
38. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994, 91:3497-3504. 10.1073/pnas.91.9.3497, 43607, 7909602.
39. Coruzzi G, Adami M, Bertaccini G. Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole. Gen Pharmacol 1995, 26:1027-1032. 10.1016/0306-3623(94)00278-U, 7557245.
40. Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res 2010, 29:44. 10.1186/1756-9966-29-44, 2876100, 20459683.
41. Matsubara T, Kusuzaki K, Matsumine A, Shintani K, Satonaka H, Uchida A. Acridine orange used for photodynamic therapy accumulates in malignantmusculoskeletal tumors depending on pH gradient. Anticancer Res 2006, 26:187-193.
42. Kusuzaki K, Murata H, Matsubara T, Satonaka H, Wakabayashi T, Matsumine A, Uchida A. Acridine orange could be an innovative anticancer agent under photon energy. In Vivo 2007, 21:205-214.
43. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 2010, 267(5):515-25. 10.1111/j.1365-2796.2010.02225.x, 20433578.
44. Abraham J, Ross E, Klickovich RJ. Cancer-related bone pain. 2009, 629-654. Bonica's management of pain. Lippincott Williams & Wilkins, Ballantyne J, Fishman SM, Rathmell JP, 4.
45. Drochioiu G. Chronic metabolic acidosis may be the cause of cachexia: body fluid pH correction may be an effective therapy. Med Hypotheses 2008, 70:1167-73. 10.1016/j.mehy.2007.11.007, 18180110.
46. Pan HL, Zhang YQ, Zhao ZQ. Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons. Mol Pain 2010, 6:85. 10.1186/1744-8069-6-85, 3004845, 21118579.
47. Okumura R, Shima K, Muramatsu T, Nakagawa K, Shimono M, Suzuki T, Magloire H, Shibukawa Y. The odontoblast as a sensory receptor cell? The expression of TRPV1 (VR-1) channels. Arch Histol Cytol 2005, 68:251-257. 10.1679/aohc.68.251, 16477145.
48. Roodman GD. Biology of Osteoclast Activation in Cancer. J Clin Oncol 2001, 19:3562-3571.
49. Porrello A, Cardelli P, Spugnini EP. Pet models in cancer research: general principles. J Exp Clin Canc Res 2004, 2:5-17.
50. Porrello A, Cardelli P, Spugnini EP. Oncology of companion animals as a model for humans: an overview of tumor histotypes. J Exp Clin Cancer Res 2006, 25:97-106.